News Briefs Crucell to Buy SBL Vaccin By PE Hub Staff - 21 November 2006 Share A- A+ 100% Crucell NV has agreed to buy Swedish biotech company SBL Vaccin AB for Euro 39.4 million in cash from 3i Group and SEB. The deal is expected to close on Thursday. www.crucell.com www.sblvaccines.se Share this:TwitterLinkedIn